It has been established that enhanced expression of IGFBP2 is associated with the progression of tumorigenesis in prostate (27), breast cancer (138), and glioma (7); however, when the expression of IGFBP2 is examined further it appears that there are certain cancer types or subpopulations of cancers, which develop with little or no expression of IGFBP2. This evidence concerns the gene IGFBP2 and breast carcinoma.